RxDoctor Payments DataLook up a doctor →

Jeffrey Royce, MD

Family Medicine · Rockford, ILNPI 1619910635

Payments from drug & device makers

$889,992in general payments, 2019–2025

Across 1,316 payments — averaging $676.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$556K
  • Amgen$133K
  • Lilly USA, LLC$75K
  • Biohaven Pharmaceutical Holding Company Ltd.$42K
  • Biohaven Pharmaceuticals, Inc.$38K
  • Teva Pharmaceuticals USA, Inc.$19K
  • plus $27K from 24 others

What the payments were for

  • Consulting fees$101,47211%
  • Speaking & faculty fees$706,93579%
  • Travel & lodging$54,8066%
  • Food & beverage$26,7023%
  • Education$770%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$889,992 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$31,779
Medicare patients
80
Services billed
361

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate135$217,552
UbrelvyUbrogepant80$105,310
QuliptaAtogepant38$52,891
Aimovig AutoinjectorErenumab-Aooe48$40,863
Dihydroergotamine Mesylate22$26,748
BotoxOnabotulinumtoxina21$25,956
Emgality PenGalcanezumab-Gnlm27$19,990
BelsomraSuvorexant18$9,882
NeuproRotigotine11$9,219
ReyvowLasmiditan Succinate13$9,188
Zolmitriptan37$6,129
Sumatriptan Succinate138$4,026
Memantine Hcl ErMemantine Hcl42$3,738
Duloxetine Hcl96$2,518
Diphenhydramine Hcl46$2,321

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$636$217,552135 claims
AbbVieUbrelvy, Qulipta, Botox$555,946$184,157139 claims
MerckBelsomra$137$9,88218 claims
Lilly USA, LLCReyvow, Olanzapine$74,726$9,45224 claims
Upsher-smith Laboratories LLCTopiramate$125$41371 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Rockford

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →